A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/23/2002	EP1250353A2 P21 derived peptides capable of inhibiting cdk/cyclin complexes
10/23/2002	EP1250348A1 Antisense modulation of daxx expression
10/23/2002	EP1250340A1 Methods and compounds for inhibiting mrp1
10/23/2002	EP1250334A2 Agents and methods for the treatment of proliferative diseases
10/23/2002	EP1250326A2 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
10/23/2002	EP1250317A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments
10/23/2002	EP1250155A1 Angiogenesis and vascular permeability modulators and inhibitors
10/23/2002	EP1250152A1 Hyaluronic acid in the treatment of cancer
10/23/2002	EP1250151A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
10/23/2002	EP1250149A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer
10/23/2002	EP1250147A1 Interferon-alpha use in the treatment of ewing's family of tumors
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP1250140A2 Combinations of a receptor tyrosine kinase inhibitor with alpha1-acidic glycoprotein binding compound
10/23/2002	EP1250139A1 Product for treating gynecomastia
10/23/2002	EP1250138A1 Fulvestrant formulation
10/23/2002	EP1250137A2 Jak/stat pathway inhibitors and the uses thereof
10/23/2002	EP1250135A1 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
10/23/2002	EP1250116A1 Pharmaceutical and cosmetic carrier or composition for topical application
10/23/2002	EP1250095A1 Versatile hydrophilic dyes
10/23/2002	EP1250094A1 Tunable indocyanine dyes for biomedical applications
10/23/2002	EP1250093A1 Novel indocyanine dyes
10/23/2002	EP1250055A1 Immune modulation with death receptor-induced apoptosis
10/23/2002	EP1066297B1 Phosphinic acid derivatives
10/23/2002	EP0869947B1 Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
10/23/2002	EP0826000B1 Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
10/23/2002	EP0785191B1 Fused indan derivatives and salts thereof
10/23/2002	EP0767170B1 Novel 4,6-diarylpyrimidine derivatives and salts thereof
10/23/2002	EP0721470B1 Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer
10/23/2002	EP0674630B1 7-HALO- AND 7$g(b),8$g(b)-METHANO-TAXOLS, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
10/23/2002	CN1376163A Highly purified cytokine activating factor and methods of use
10/23/2002	CN1376157A Triazolopurine derivatives, drug compositions containing the same and adenosine A3 receptor affinitive agents
10/23/2002	CN1376156A Benzodiazepin derivatives, the production and use thereof
10/23/2002	CN1376155A Thiourea and isothiourea derivatives for inhibiting RAS-transformed cell growth
10/23/2002	CN1376148A Rate-controlled particles
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1376073A Method of expressing antigen on the surface of an antigen-presenting cell by photochemical internalisation
10/23/2002	CN1376071A Anti cancer agent and method of treatment of cancer
10/23/2002	CN1376064A Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
10/23/2002	CN1376062A Use of amino acids for making medicine for treating to insulin-resistance
10/23/2002	CN1376036A Metal-containing compositions, preparations and uses
10/23/2002	CN1375494A Iso-indolo-indolone compound, their preparation methods and drug compositions comprising the same
10/23/2002	CN1375490A Novel indeno indolone compound, its preparation method and drug composition comprising the same
10/23/2002	CN1375332A Composition and method for making Akt cancer gene inactivate and activating P38 precell fade-out gene
10/23/2002	CN1375314A Fermented soybean extracted liquid and composite medicine containing the said liquid
10/23/2002	CN1375305A Externally applied anticancer analgesic ointment
10/23/2002	CN1375301A Application of pilose gerbera herb in preparing antineoplastic medicine
10/23/2002	CN1375294A Arsenic trioxide powder for injection
10/23/2002	CN1092977C Anti-cancer medicine
10/23/2002	CN1092973C Use of mastic or mastic lipophilia extract in preparation of drug for treatment of alzheimer's disease
10/23/2002	CN1092972C Medicine for resisting tumor and carcinomatosis
10/23/2002	CN1092969C Anticancer Chinese medicine
10/23/2002	CN1092942C Natural and health-care food and its preparation method
10/23/2002	CA2381875A1 Multioligoanilinated fullerenes
10/22/2002	US6469184 Coupling a cyclopentenone with a cyclic carbonyl ylide dipole
10/22/2002	US6469182 Intermediates in the preparation of macrocyclic analogs
10/22/2002	US6469180 3-(1-methyl-3-indolyl)-4-(1-methyl-6-nitro-3-indolyl)-1h -pyrrole-2,5,-dione which is substantially free of crystalline compound prepared by dissolving crystalline in a supercritical fluid then evaporating
10/22/2002	US6469179 Dissolving crystalline (bis-indol-3-yl) 3-pyrroline imide derivative in an organic solvent, extracting the solvent with supercritical liquid nitrogen or carbon dioxide
10/22/2002	US6469171 Syntheses of a variety of lamellarin compounds and analogues
10/22/2002	US6469162 Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis
10/22/2002	US6469146 Radiopharmaceutical products suitable for the selective labeling of lymphocytes, and their preparation
10/22/2002	US6469144 Apo-2li (apo-2 ligand inhibitor, related to apoptosis) monoclonal antibodies
10/22/2002	US6469061 Use of members of the plant stress hormone family termed ?jasmonates?, for suppressing and killing mammalian cancer cells that represent major types of human malignancies
10/22/2002	US6469058 For the treatment of nonsmall cell lung cancer
10/22/2002	US6469056 Pharmaceutically active compounds, their preparation and use as ECE-inhibitors
10/22/2002	US6469050 7-hexanoyltaxol and methods for preparing the same
10/22/2002	US6469045 Thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products; oral administration
10/22/2002	US6469043 Antiangiogenic agent with antitumor, antimetastatic properties which shows high safety
10/22/2002	US6469032 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
10/22/2002	US6469022 By inhibition of the p-glycoprotein efflux pump, a multidrug transporter, in the intestinal mucosa; allowing intracellular accumulation of drug
10/22/2002	US6469020 Hydroxamic and carboxylic acid derivatives
10/22/2002	US6469018 Compounds
10/22/2002	US6469013 Therapeutic compounds
10/22/2002	US6469004 Benzoheterocycles and their uses as MEK inhibitors
10/22/2002	US6469000 1,3-diheterocyclic metalloprotease inhibitors
10/22/2002	US6468986 Composition comprising polynucleotide and polycationic agent which exhibits net positive electrical charge at physiological ph, and is capable of mediating entry of polynucleotides into cell
10/22/2002	US6468985 Administering nucleic acid molecule encoding retinoblastoma protein-interacting zinc finger protein at or adjacent to site of tumor, wherein protein comprises specified amino acid sequence and is expressed in tumor cell and reduces its growth
10/22/2002	US6468983 RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
10/22/2002	US6468980 Composition comprising cancer chemotherapeutic agent and potentiating agent selected from group consisting of vitamin c metabolites or ascorbic acid-derived furanones
10/22/2002	US6468798 Liposome-nucleic acid complexes are prepared then delivered via aerosol to the lung airway; for transforming pulmonary cells and treating lung diseases
10/22/2002	US6468756 Methods of identifying compounds that bind to SNORF25 receptors
10/22/2002	US6468546 Compositions and methods for therapy and diagnosis of ovarian cancer
10/22/2002	US6468542 Germination activated Ganoderma lucidum spores and method for producing the same
10/22/2002	US6468540 Immunotherapeutic stress protein-peptide complexes against cancer
10/22/2002	US6468530 Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
10/22/2002	US6468529 Fab fragment of a monoclonal antibody; binds to c-met receptor; cancer treatment
10/22/2002	US6468528 Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth
10/22/2002	US6468519 Polyanhydrides with biologically active degradation products
10/22/2002	US6468503 Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
10/22/2002	US6468502 Paramagnetic macromolecules with higher proton relaxivity; lower dosage and increased signal intensity; detecting vascular diseases; differentiating tissue blood supply levels; distinguishing myocardial infarction from ischemia
10/22/2002	CA2253914C Camptothecin-skeleton compounds isolated from mappia foetida and the use thereof as syntones for novel medicaments as well as therapeutical agents
10/22/2002	CA2218477C Rna photocleavage using texaphyrins
10/22/2002	CA2185712C Enhanced virus-mediated dna transfer
10/22/2002	CA2118670C Pharmaceutical compositions in semisolid form and a device for administration thereof
10/22/2002	CA2106954C Dry starch-iodine pharmaceutical formulations
10/22/2002	CA2095335C Cell growth inhibitors
10/17/2002	WO2002082077A2 Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes
10/17/2002	WO2002082076A2 Renal cell carcinoma tumor markers
10/17/2002	WO2002082044A2 Method of imaging cell death in vivo
10/17/2002	WO2002081728A2 Quinoline inhibitors of hyak1 and hyak3 kinases

1 ... 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 ... 2211